Show simple item record

dc.contributor.authorMinchom, A
dc.contributor.authorYuan, W
dc.contributor.authorCrespo, M
dc.contributor.authorGurel, B
dc.contributor.authorFigueiredo, I
dc.contributor.authorWotherspoon, A
dc.contributor.authorMiranda, S
dc.contributor.authorRiisnaes, R
dc.contributor.authorFerreira, A
dc.contributor.authorBertan, C
dc.contributor.authorPereira, R
dc.contributor.authorClarke, M
dc.contributor.authorBaker, C
dc.contributor.authorAng, JE
dc.contributor.authorFotiadis, N
dc.contributor.authorTunariu, N
dc.contributor.authorCarreira, S
dc.contributor.authorPopat, S
dc.contributor.authorO'Brien, M
dc.contributor.authorBanerji, U
dc.contributor.authorde Bono, J
dc.contributor.authorLopez, J
dc.date.accessioned2020-04-14T15:27:54Z
dc.date.issued2020-03-01
dc.identifier.citationJournal for immunotherapy of cancer, 2020, 8 (1)
dc.identifier.issn2051-1426
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3592
dc.identifier.eissn2051-1426
dc.identifier.doi10.1136/jitc-2020-000713
dc.description.abstractBACKGROUND: This case represents an exceptional response to pembrolizumab in a patient with epithelioid mesothelioma with a further response on rechallenge. CASE PRESENTATION: A 77-year-old woman with advanced epithelioid mesothelioma extensively pretreated with chemotherapy demonstrated a prolonged response of 45 months to 52 cycles of pembrolizumab. On rechallenge with pembrolizumab, further disease stability was achieved. Serial biopsies and analysis by immunohistochemistry and immunofluorescence demonstrated marked immune infiltration and documented the emergency of markers of immune exhaustion. Whole exome sequencing demonstrated a reduction in tumor mutational burden consistent with subclone elimination by immune checkpoint inhibitor (CPI) therapy. The relapse biopsy had missense mutation in BTN2A1. CONCLUSION: This case supports rechallenge of programme death receptor 1 inhibitor in cases of previous CPI sensitivity and gives molecular insights.
dc.formatPrint
dc.languageeng
dc.language.isoeng
dc.publisherBMJ PUBLISHING GROUP
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0
dc.subjectHumans
dc.subjectMesothelioma
dc.subjectLung Neoplasms
dc.subjectPleural Neoplasms
dc.subjectPrognosis
dc.subjectRetreatment
dc.subjectAged
dc.subjectFemale
dc.subjectAntibodies, Monoclonal, Humanized
dc.subjectBiomarkers, Tumor
dc.subjectB7-H1 Antigen
dc.subjectMesothelioma, Malignant
dc.titleMolecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab.
dc.typeJournal Article
dcterms.dateAccepted2020-02-05
rioxxterms.versionofrecord10.1136/jitc-2020-000713
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc/4.0
rioxxterms.licenseref.startdate2020-03
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJournal for immunotherapy of cancer
pubs.issue1
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine (de Bono Prostate)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Treatment of thoracic tumours
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Treatment of thoracic tumours/Treatment of thoracic tumours (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine (de Bono Prostate)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Treatment of thoracic tumours
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Treatment of thoracic tumours/Treatment of thoracic tumours (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume8
pubs.embargo.termsNot known
icr.researchteamMedicine (de Bono Prostate)
icr.researchteamCancer Biomarkers
icr.researchteamClinical Pharmacology – Adaptive Therapy
icr.researchteamProstate Cancer Targeted Therapy Group
icr.researchteamThoracic Oncology
icr.researchteamTreatment of thoracic tumours
dc.contributor.icrauthorMinchom, Anna
dc.contributor.icrauthorGurel, Bora
dc.contributor.icrauthorMiranda, Susana
dc.contributor.icrauthorPereira, Ana Rita
dc.contributor.icrauthorCarreira, Suzanne
dc.contributor.icrauthorBanerji, Udai
dc.contributor.icrauthorDe Bono, Johann


Files in this item

Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc/4.0